Cargando…

Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients. OBJECTIVE: To conduct a meta-analysis and estimate the efficacy and safety of FMT for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hui-jun, Zhang, Xiao-jing, Zhang, Na-na, Yan, Bin, Xu, Ke-ke, Peng, Li-hua, Pan, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202577/
https://www.ncbi.nlm.nih.gov/pubmed/35719141
http://dx.doi.org/10.3389/fnut.2022.890357
_version_ 1784728558462042112
author Zhao, Hui-jun
Zhang, Xiao-jing
Zhang, Na-na
Yan, Bin
Xu, Ke-ke
Peng, Li-hua
Pan, Fei
author_facet Zhao, Hui-jun
Zhang, Xiao-jing
Zhang, Na-na
Yan, Bin
Xu, Ke-ke
Peng, Li-hua
Pan, Fei
author_sort Zhao, Hui-jun
collection PubMed
description BACKGROUND: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients. OBJECTIVE: To conduct a meta-analysis and estimate the efficacy and safety of FMT for the treatment of IBS patients with subgroup analyses to explore the most effective way of FMT for IBS. METHODS: All eligible studies were searched from PubMed, Embase, Web of Science, and the Cochrane Library through multiple search strategies. Data were extracted from studies comprising the following criteria: double-blind, randomized controlled trials (RCTs) that compared the efficacy of FMT with placebo for adult patients (≥18 years old) with IBS. A meta-analysis was performed to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs). RESULTS: A total of seven RCTs comprising 489 subjects were eligible for this meta-analysis. Pooled data showed no significant improvement of global IBS symptoms in patients with FMT compared with placebo (RR = 1.34; 95% CI 0.75–2.41, p = 0.32). A significant heterogeneity was observed among the studies (I(2) = 83%, p < 0.00001). There was no significant evidence of funnel plot asymmetry (Egger's test, p = 0.719; Begg's test, p = 1.000), indicating no existence of publication bias. Subgroup analyses revealed that FMT operated by invasive routes, including gastroscope, colonoscope, and nasojejunal tube, significantly improved global IBS symptoms (RR = 1.96; 95% CI 1.23–3.11, p = 0.004) with heterogeneity (I(2) = 57%, p = 0.06) and an NNT of 3 (95% CI 2–14). However, FMT delivered via oral capsules showed a negative impact on patients with IBS (RR = 0.56; 95% CI 0.33–0.96, p = 0.03) with a low heterogeneity (I(2) = 39%, p = 0.2) and an NNH of 3 (95% CI 2–37). CONCLUSION: The current evidence from RCTs with all routes of FMT does not show significant global improvement in patients with IBS. However, FMT operated by invasive routes significantly improved global IBS symptoms.
format Online
Article
Text
id pubmed-9202577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92025772022-06-17 Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials Zhao, Hui-jun Zhang, Xiao-jing Zhang, Na-na Yan, Bin Xu, Ke-ke Peng, Li-hua Pan, Fei Front Nutr Nutrition BACKGROUND: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients. OBJECTIVE: To conduct a meta-analysis and estimate the efficacy and safety of FMT for the treatment of IBS patients with subgroup analyses to explore the most effective way of FMT for IBS. METHODS: All eligible studies were searched from PubMed, Embase, Web of Science, and the Cochrane Library through multiple search strategies. Data were extracted from studies comprising the following criteria: double-blind, randomized controlled trials (RCTs) that compared the efficacy of FMT with placebo for adult patients (≥18 years old) with IBS. A meta-analysis was performed to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs). RESULTS: A total of seven RCTs comprising 489 subjects were eligible for this meta-analysis. Pooled data showed no significant improvement of global IBS symptoms in patients with FMT compared with placebo (RR = 1.34; 95% CI 0.75–2.41, p = 0.32). A significant heterogeneity was observed among the studies (I(2) = 83%, p < 0.00001). There was no significant evidence of funnel plot asymmetry (Egger's test, p = 0.719; Begg's test, p = 1.000), indicating no existence of publication bias. Subgroup analyses revealed that FMT operated by invasive routes, including gastroscope, colonoscope, and nasojejunal tube, significantly improved global IBS symptoms (RR = 1.96; 95% CI 1.23–3.11, p = 0.004) with heterogeneity (I(2) = 57%, p = 0.06) and an NNT of 3 (95% CI 2–14). However, FMT delivered via oral capsules showed a negative impact on patients with IBS (RR = 0.56; 95% CI 0.33–0.96, p = 0.03) with a low heterogeneity (I(2) = 39%, p = 0.2) and an NNH of 3 (95% CI 2–37). CONCLUSION: The current evidence from RCTs with all routes of FMT does not show significant global improvement in patients with IBS. However, FMT operated by invasive routes significantly improved global IBS symptoms. Frontiers Media S.A. 2022-05-27 /pmc/articles/PMC9202577/ /pubmed/35719141 http://dx.doi.org/10.3389/fnut.2022.890357 Text en Copyright © 2022 Zhao, Zhang, Zhang, Yan, Xu, Peng and Pan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Zhao, Hui-jun
Zhang, Xiao-jing
Zhang, Na-na
Yan, Bin
Xu, Ke-ke
Peng, Li-hua
Pan, Fei
Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
title Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
title_full Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
title_fullStr Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
title_short Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
title_sort fecal microbiota transplantation for patients with irritable bowel syndrome: a meta-analysis of randomized controlled trials
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202577/
https://www.ncbi.nlm.nih.gov/pubmed/35719141
http://dx.doi.org/10.3389/fnut.2022.890357
work_keys_str_mv AT zhaohuijun fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials
AT zhangxiaojing fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials
AT zhangnana fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials
AT yanbin fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials
AT xukeke fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials
AT penglihua fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials
AT panfei fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials